News After phase 3 hit, Spine seeks path forward for pain drug The first phase 3 readout with Spine BioPharma's drug candidate for chronic low back pain has proved disappointing.
News ChatGPT can cut review times for clinical trial eligibility ChatGPT can't replace humans when it comes to checking patient eligibility to take part in clinical trials, but it can save time and money.
News Lilly trumpets heart health data with Mounjaro Eli Lilly has raised the stakes in its rivalry with Novo Nordisk on GLP-1 drugs for diabetes, with new data for Mounjaro on cardiovascular outcomes.
News GSK suffers a setback with its TIM-3 programme GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor TIM-3.
News Celcuity eyes big market opportunity after breast cancer win Celcuity shares rocket on a big win for its lead drug gedatolisib in advanced breast cancer, catapulting its value to almost $1.4 billion.
News Bayer files HER2+ lung cancer drug in China Bayer files its oral HER2+ lung cancer drug in China, as it extends a race to market with rival Boehringer Ingelheim.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
